Why the study?
Does exercise restriction prevent the development of overt ARVC in genotype-positive family members?
Does exercise restriction prevent the development of overt ARVC in genotype-positive family members?
Answers are grounded in this paper and cite their sources.
Restricting exercise to less than 150 minutes of mild-to-moderate activity per week may significantly reduce the penetrance of ARVC in genotype-positive family members.
This editorial refers to ‘Exercise restriction is protective for genotype-positive family members of arrhythmogenic right ventricular cardiomyopathy patients’, by W. Wang et al., on pages 1270--1278. Clinical genetics places important emphasis on the family as the unit of care such that investigations are expanded from the proband to those who may carry the same genetic mutation but have few if any evidence of the disease (the so-called ‘genotype positive/phenotype negative’ patient).1 Furthermore, the increased use of gene panels in diagnostic testing and the controversial practice of genetic screening have the potential to identify genetic variants and mutations in subjects without a clear phenotypic correlation. However, the identification of gene mutations in asymptomatic individuals creates a clinical conundrum. Will they develop a cardiomyopathy? What can be done to minimize disease expression? How do we balance the imposition and risk of preventive therapies against the risks of potential disease and its consequences? Our patients all perceive risk differently and decision-making cannot be standardized. However, it is critical that decisions are based on the best possible evidence. The group of investigators from Johns Hopkins University have contributed an enormous amount to the clinical guidance of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), particularly in relation to the interaction between exercise and disease and, in the current issue of Europace, Wang et al.2 provide the strongest evidence to date that a combination of prolonged and intense exercise—they use the term ‘exercise dose’—contributes to disease expression in genetically predisposed individuals. An association between intense endurance exercise and ARVC has already been established in several observational studies.3–8 Patients with ARVC who had participated in regular endurance exercise were observed to develop symptoms ∼10 years earlier, including a greater and earlier incidence of ventricular arrhythmias and heart failure. Athletic ARVC patients also develop biventricular dysfunction more frequently than sedentary ARVC patients.4–8 Thus, recommendations have embraced the concept that intense and/or endurance exercise should be avoided in family members with a genetic mutation.9 However, this experience was predominantly derived from probands in whom disease is expression was more prevalent and severe. In contrast, the majority of family members identified through cascade screening are asymptomatic10 and broad-based community genetic screening has suggested that gene mutations are uncommonly associated with disease manifestations.11 Thus, it may be somewhat draconian to be advising against exercise and all of the associated health benefits, when the risk of developing disease may be too low to be realized. Moreover, patients like to have quantifiable exercise recommendations, and current guidance stating ‘avoidance of frequent high intensity or competitive endurance exercise’ is frustratingly vague.9 This in turn will lead to lower adherence to such guidance, and hence more patients developing pathology. We commend Wang et al.2 for their effort to better inform guidance in this respect. They present a study comprised exclusively of geno-positive ARVC family members (81% with plakophilin-2 mutations), excluding probands. Lifetime exercise after the age of 10 years was quantified as a product of time and intensity (MET-hours) and this exercise ‘dose’ was greater in family members who met diagnostic criteria for ARVC or experienced a ventricular arrhythmia. Restriction to <150 min of mild to moderate exercise per week (American Heart Association guideline minimum) emerges as a potentially useful cut-off to prevent overt ARVC. Below this threshold, only 1 of 20 individuals (5%) developed ARVC, as compared with 40 of 81 (50%) of subjects exercising above this amount. The evidence presented by Wang et al.2 suggests that the current recommendations might need to be more restrictive, but more importantly, can be better quantified. Some interesting additional novel observations are made. Wang et al.2 observed that the association between exercise and ARVC expression was even more apparent in females than males. This surprising finding may have a biological explanation. Another explanation may relate to the persisting and marked gender disparity in sports competition12 that might imply a greater range of exercise participation in females and thus more power for identifying associations. The lower proportion of females among probands might also be an expression of the same lower exercise ‘exposition’. Another intriguing observation from the data of Wang et al. was that a combination of exercise duration and intensity that was required to elicit ARVC whereas intensity alone was not associated with greater penetrance. This largely agrees with the data from Lie et al.13 derived from a mixed cohort of proband and family members and also aligns with the related syndrome of ‘exercise-induced ARVC’ or ‘gene-elusive’ ARVC that is seen almost exclusively in athletes regularly training and competing at very high intensity for prolonged durations.14 On the other hand, quantifying exercise remains a difficult task which is still largely unsatisfactory, not only for research purposes, but also because patients want more precise quantitative guidance. The use of retrospective questionnaires is prone to recall bias and a ‘regression to the mean’ in which those performing little exercise tend to overstate and athletes often understate activity. The increasingly widespread use of activity monitors, smart watches, and tracking apps provides a valuable opportunity to sharpen our research tools and identify differences in exercise habits that may enable us to prescribe exercise with greater specificity. Furthermore, more accurate quantification of activity may enable us to extend the lessons learnt from ARVC to other cardiomyopathy types. Recently, an association between competitive sports participation and severity of Lamin A/C cardiomyopathy was reported,15 and it is likely that the powerful haemodynamic stimulus on cardiac remodelling may influence disease expression in a range of cardiomyopathic conditions. There are several interventional therapies to be considered when managing the patient with ARVC, ranging from beta-blockers to implantable cardioverter-defibrillators. Good health outcomes are also dependent on patient ownership of their health and the ability to control elements that determine outcome. Arrhythmogenic right ventricular cardiomyopathy is a situation where the evidence for lifestyle therapy may be as strong as for interventional therapies. It is imperative that management of ARVC patients and family members involves a detailed inquiry about exercise habits and specific instructions about how exercise may need to be modified to avoid disabling or life-threatening symptoms. We thank the Johns Hopkins team for refining the evidence base that we can use to inform contemporary shared care. Conflict of interest: H.H. has received no personal funding. He received unconditional research grants from Medtronic, Daiichi Sankyo, Boehringer-Ingelheim, Bayer, Pfizer-BMS, Biotronik, Abbott, and Bracco Imaging through the University of Hasselt or Antwerp University. A.L.G. declared no conflict of interest. The opinions expressed in this article are not necessarily those of the Editors of Europace or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Gerche et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: